Substitutions in a major histocompatibility complex class II-restricted human immunodeficiency virus type 1 gp120 epitope can affect CD4+ T-helper- cell function

Journal of Virology

Volumn 72, Issue 7, 1998, Pages 5840-5844

  Lekutis, Christine ^a,b   Letvin, Norman L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; EPITOPE; GLYCOPROTEIN GP 120; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CYTOKINE RELEASE; HELPER CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LIGAND BINDING; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN VARIANT; RHESUS MONKEY; VIRUS MUTATION; VIRUS REPLICATION;

EID: 0031746017     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.7.5840-5844.1998     Document Type: Article

References (34)

1. Bertoletti, A., A. Sette, F. V. Chisari, A. Penna, M. Levrero, M. DeCarli, F. Fiaccadori, and C. Ferrari. 1994. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 369:407-410.
2. Boehncke, W.-H., T. Takeshita, C. D. Pendleton, R. A. Houghton, S. Sadegh-Nasseri, L. Racioppi, J. A. Berzofsky, and R. N. Germain. 1993. The importance of dominant negative effects of amino acid side chain substitutions in peptide-MHC molecule interactions and T cell recognition. J. Immunol. 150: 331-341.
3. Callahan, K. M., M. M. Fort, E. A. Obah, E. L. Reinherz, and R. F. Siliciano. 1990. Genetic variability in HIV-1 gp120 affects interactions with HLA molecules and T cell receptor. J. Immunol. 144:3341-3346.
4. Calman, A., and B. Peterlin. 1987. Mutant human B cell lines deficient in class II major histocompatibility complex transcription. J. Immunol. 139: 2489-2495.
5. Clerici, M., and G. M. Shearer. 1993. A Th1-to-Th2 switch is a critical step in the etiology of HIV infection. Immunol. Today 14:107-111.
6. Davies, M., and R. Kaufman. 1992. The sequence context of the initiation codon in the encephalomyocarditis virus leader modulates the efficiency of internal translation initiation. J. Virol. 66:1924-1932.
7. DeMagistris, M. T., J. Alexander, M. Coggeshall, A. Altman, F. C. A. Gaeta, H. M. Grey, and A. Sette. 1992. Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell 68:625-634.
8. Evagold, B. D., and P. M. Allen. 1991. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science 252:1308-1310.
9. Fernandez, M. H., A. Faith, J. A. Higgins, J. Weber, and A. D. M. Rees. 1995. The effect of a single amino acid substitution within the V3 loop of HIV-1 gp120 on HLA-DR1-restricted CD4 T-cell recognition. Immunology 85:176-183.
10. Fernandez, M. H., S. J. Fidler, R. J. Pitman, J. N. Weber, and A. D. M. Rees. 1997. CD4+ T-cell recognition of diverse clade B HIV-1 isolates. AIDS 11: 281-288.
11. Fisher, A. G., B. Ensoli, D. Looney, A. Rose, R. C. Gallo, M. S. Saag, G. M. Shaw, B. H. Hahn, and F. Wong-Staal. 1988. Biologically diverse molecular variants within a single HIV-1 isolate. Nature 334:444-447.
12. Hahn, B. H., G. M. Shaw, M. E. Taylor, R. R. Redfield, P. D. Markham, S. Z. Salahuddin, F. Wong-Staal, R. C. Gallo, E. S. Parks, and W. P. Parks. 1986. Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS. Science 232:1548-1553.
13. Jameson, S. C., and M. J. Bevan. 1995. T cell receptor antagonists and partial agonists. Immunity 2:1-11.
14. Kent, S. J., P. D. Greenberg, M. C. Hoffman, R. E. Akridge, and M. J. McElrath. 1947. Antagonism of vaccine-induced HIV-1-specific CD4+ T cells by primary HIV-1 infection. J. Immunol. 158:807-815.
15. Kersh, G. J., and P. M. Allen. 1996. Essential flexibility in the T-cell recognition of antigen. Nature 380:495-498.
16. Klenerman, P., S. Rowland-Jones, S. McAdam, J. Edwards, S. Daenke, D. Lalloo, B. Koppe, W. Rosenberg, D. Boyd, A. Edwards, P. Giangrande, R. E. Phillips, and A. J. McMichael. 1994. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants. Nature 369:403-407.
17. Lekutis, C., and N. L. Letvin. 1997. HIV-1 envelope-specific CD4+ T helper cells from simian/human immunodeficiency virus-infected rhesus monkeys recognize epitopes restricted by MHC class II DRB1 *0406 and DRB*W201 molecules. J. Immunol. 159:2049-2057.
18. Lekutis, C., J. W. Shiver, M. A. Liu, and N. L. Letvin. 1997. HIV-1 env DNA vaccine administered to rhesus monkeys elicits MHC class II-restricted CD4+ T helper cells that secrete IFNγ and TNFα. J. Immunol. 158:4471-4477.
19. Li, J., C. I. Lord, W. Haseltine, N. L. Letvin, and J. Sodroski. 1992. Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoprotein. J. Acquired Immune Defic. Syndr. 5:639-646.
20. Manca, F., J. A. Habeshaw, A. G. Dalgleish, D. Fenoglio, G. L. Pira, and E. E. Sercarz. 1993. Role of flanking variable sequences in antigenicity of consensus regions of HIV gp120 for recognition by specific human T helper clones. Eur. J. Immunol. 23:269-274.
21. Myers, G., B. Korber, B. Foley, K.-T. Jeang, J. W. Mellors, and S. Wain-Hobson. 1996. Human retrovirus and AIDS. Los Alamos National Laboratory, Los Alamos, N.Mex.
22. Nicholson, L. B., J. M. Greer, R. A. Sobel, M. B. Lees, and V. K. Kuchroo. 1995. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomylelitis. Immunity 3:397-405.
23. Rabin, H., B. H. Neubauer, R. F. Hopkins III, E. K. Dzhikidze, Z. V. Shevtsova, and B. A. Lapin. 1977. Transforming activity and antigenicity of an Epstein-Barr-like virus from lymphoblastoid cell lines of baboons with lymphoid disease. Intervirology 8:240-249.
24. Rabinowitz, J. D., C. Beeson, C. Wulfing, K. Tate, P. M. Allen, M. M. Davis, and H. M. McConnell. 1996. Altered T cell receptor ligands trigger a subset of early T cell signals. Immunity 5:125-135.
25. Rammensee, H.-G., T. Friede, and S. Stevanovic. 1995. MHC ligands and peptide motifs: first listing. Immunogenetics 41:178-228.
26. Ratto, S., K. V. Sitz, A. M. Scherer, L. D. Loomis, J. H. Cox, R. R. Redfield, and D. L. Birx. 1996. CD4+ T-lymphocyte lines developed from HIV-1-seropositive patients recognize different epitopes within the V3 loop. J. Acquired Immune Defic. Syndr. 11:128-136.
27. Reay, P. A., R. M. Kantor, and M. M. Davis. 1994. Use of global amino acid replacements to define the requirements for MHC binding and T cell recognition of moth cytochrome c (93-103). J. Immunol. 152:3946-3957.
28. Rosenberg, E. S., J. M. Billingsley, A. M. Caliendo, S. L. Boswell, P. E. Sax, S. A. Kalams, and B. D. Walker. 1997. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278:1447-1450.
29. Saag, M. S., B. H. Hahn, J. Gibbons, Y. X. Li, E. S. Parks, W. P. Parks, and G. M. Shaw. 1988. Extensive variation of human immunodeficiency virus type-1 in vivo. Nature 334:440-444.
30. Sakuragi, S., R. Shibata, R. Mukai, T. Komatsu, M. Fukasawa, H. Sakai, J.-I. Sakuragi, M. Kawamura, K. Ibuki, M. Hayami, and A. Adachi. 1992. Infection of macaque monkeys with a chimeric human and simian immunodeficiency virus. J. Gen. Virol. 73:2983-2987.
31. Siliciano, R. F., T. Lawton, C. Knall, R. W. Karr, P. Berman, T. Gregory, and E. L. Reinherz. 1988. Analysis of host-virus interactions in AIDS with anti-gp120 T cell clones: effect of HIV sequence variation and a mechanism for CD4+ cell depletion. Cell 54:561-575.
32. Sinigaglia, F., and J. Hammer. 1995. Motifs and supermotifs for MHC class II binding peptides. J. Exp. Med. 181:449-451.
33. Tsitoura, D. C., A. Verhoef, C. M. Gelder, R. E. O'Hehir, and J. R. Lamb. 1996. Altered T cell ligands derived from a major house dust mite allergen enhance IFNγ but not IL-4 production by human CD4+ T cells. J. Immunol. 157:2160-2165.
34. Windhagen, A., C. Seholz, P. Hollsberg, H. Fukaura, A. Sette, and D. A. Hafler. 1995. Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. Immunity 2:373-380.